A Phase 2 interventional study of Cevostamab and Pomalidomide in Multiple Myeloma, sponsored by Hoffmann-La Roche. Recruiting at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.
Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one is the 19th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 30th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 15 more countries
Ages 18+
Genentech, Inc. · Sites in Australia, Korea, Republic of
Ages 18+
Hoffmann-La Roche · Sites in Australia, France, Germany and 3 more countries
Ages 18+
Genentech, Inc. · Sites in Australia, Israel, Korea, Republic of
Ages 18+
Genentech, Inc. · Sites in United States, Australia, Canada and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 2
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is close to the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 90 across the 29 interventional studies, 662 across the 1 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Multiple Myeloma by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05646836Genentech, Inc.A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | 2026-11-18 |
| NCT05535244Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma | 2027-02-26 |
| NCT05927571Genentech, Inc.A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cevostamab will be combined with pomalidomide and dexamethasone as the experimental treatment in this study. Participants will receive Cevostamab as per the schedule in the protocol.
Drug: Cevostamab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Tocilizumab
Participants will receive cevostamab as per the schedule given in the protocol.
Also known as: RO7187797
Pomalidomide will be administered as per the schedule given in the protocol.
Dexamethasone will be administered as a premedication as per the schedule given in the protocol.
Tocilizumab may be used as rescue medication for participants who experience a cytokine release syndrome (CRS) event.
Also known as: Actemra/RoActemra
Overall Response Rate (ORR) as assessed by an Independent Review Committee
Time frame: Up to approximately 3 years
ORR, as assessed by the Investigator
Time frame: Up to approximately 3 years
Rate of Very Good Partial Response (VGPR) or Better
Time frame: Up to approximately 3 years
Complete Response/Stringent Complete Response (CR/sCR) Rate
Time frame: Up to approximately 3 years
Duration of Response (DOR)
Time frame: Up to approximately 3 years
Progression-free Survival (PFS)
Time frame: Start of study treatment to first date of disease progression or death from any cause, whichever occurs first (up to approximately 3 years)
Overall Survival (OS)
Time frame: Baseline up until death from any cause (up to approximately 3 years)
MRD-negative CR rate at 9 months measured in bone marrow aspirate by next-generation sequencing (NGS)
Time frame: At 9 months
Overall MRD-Negative Complete Response Rate
Time frame: Up to approximately 3 years
Time to Response (TTR)
Time frame: Baseline up to approximately 3 years
Time to Better Response (TTBR)
Time frame: Baseline up to approximately 3 years
Progression-Free Survival 2 (PFS2)
Time frame: Up to approximately 3 years
Time to Confirmed Deterioration in the Disease Symptoms Scale of the EORTC QLQ-MY20
Time frame: Up to approximately 3 years
Time to Confirmed Deterioration in the Global Health Status/Quality of Life (GHS/QoL) of the EORTC QLQ-Core 30 (C30)
Time frame: Up to approximately 3 years
Incidence and Severity of Adverse Events (AEs)
Time frame: Up to approximately 3 years
Change From Baseline in the Disease Symptoms Scale of the EORTC QLQ-MY20
Time frame: Baseline and up to 3 years
Change From Baseline in the GHS/QoL of the EORTC QLQ-Core 30 (C30)
Time frame: Baseline and up to 3 years
Change From Baseline in Fatigue as Assessed by the EORTC QLQ-C30
Time frame: Baseline and up to 3 years
Time to Confirmed Deterioration in Fatigue as Assessed by the EORTC QLQ-C30
Time frame: Up to approximately 3 years
Percentage of Participants Experiencing Clinically Meaningful Improvement in Disease Symptoms as Assessed by the EORTC QLQ-MY20
Time frame: Up to approximately 3 years
Percentage of Participants Experiencing Clinically Meaningful Improvement in GHS/QoL as Assessed by the EORTC QLQ-C30
Time frame: Up to approximately 3 years
Percentage of Participants Experiencing Clinically Meaningful Improvement in Fatigue as Assessed by the EORTC QLQ-C30
Time frame: Up to approximately 3 years
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline
Time frame: Baseline
Percentage of Participants with ADAs to Cevostamab during the Study
Time frame: Up to approximately 3 years
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Nov 2026 (actual). Primary completion is estimated for Apr 2029, 29 months after the start.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 29 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cevostamab